Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine with CEV Chemotherapy for Retinoblastoma
NCT00110110Phase 2Active, not recruiting
- Sponsor
- SickKids
- Start
- Jun 2004
- Primary completion
- Apr 2016
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine in retinoblastoma (Rb), sponsored by SickKids. Primary endpoint: Proportion of eyes that remain relapse-free without external beam radiotherapy and/or enucleation at 5 years. Started Jun 2004; status: active, not recruiting.
02
Drugs
cyclosporine
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00110110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110110.